JLJie Lu

Jie Lu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jie Lu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Guanzhao Liang

    Department of Dermatology, The Affiliated Hospital of Chengde Medical College, Chengde, Hebei 067000, P.R. China

    2 shared publications
  • Haitao Lu

    Department of Dermatology, The Affiliated Hospital of Chengde Medical College, Chengde, Hebei 067000, P.R. China

    2 shared publications
  • Li-Xin Sun

    The Affiliated Hospital of Chengde Medical College, Chengde, 067000, Hebei Province, China

    2 shared publications
  • Min Li

    Peking University Health Science Center

    2 shared publications
  • Minglei Ding

    Department of Dermatology, The Affiliated Hospital of Chengde Medical College, Chengde, Hebei 067000, P.R. China

    2 shared publications
  • Ning Yang

    The Affiliated Hospital of Chengde Medical College

    2 shared publications

Latest Publications

  • Retraction
    Open Access

    [Retracted] Metformin upregulates E‑cadherin and inhibits B16F10 cell motility, invasion and migration

    by Guanzhao Liang, Minglei Ding, Haitao Lu, Na Cao, Yandong Niu, Yang Gao, Jie Lu

    Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

  • Retracted
    Open Access

    Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration

    by Guanzhao Liang, Minglei Ding, Haitao Lu, NA Cao, Yandong Niu, Yang Gao, Jie Lu

    Malignant melanoma is a highly metastatic cancer, and has a poor prognosis once metastasis has occurred. E-cadherin downregulation is associated with a poorer prognosis in various types of cancer, including lung, ovarian, cervical and prostate. In the majority of cancer cell lines, E-cadherin upregulation inhibits cell motility, migration and invasiveness, and reduces tumor metastasis in in vivo models. In the present study, the inhibitory effects of metformin on the motility, invasion and migration of the B16F10 murine melanoma cell line, and the possible molecular mechanisms underlying this effect were investigated. B16F10 cells were treated with various concentrations of metformin for 24 h and their motility, migration and invasion were tested using a wound-healing assay, a migration assay and a matrigel invasion assay, respectively. Furthermore, the expression of E-cadherin was measured by immunocytochemistry, western blotting and reverse transcription-quantitative polymerase chain reaction. The results showed that metformin effectively upregulated the expression of E-cadherin, and inhibited B16F10 cell motility, migration and invasion, in a dose-dependent manner. This suggested that the inhibition of motility, migration and invasion of B16F10 cells by metformin may be associated with the upregulation of E-cadherin expression, indicating that metformin may have a role in the treatment of melanoma.


  • Cytokine production suppression by culture supernatant of B16F10 cells and amelioration by Ganoderma lucidum polysaccharides in activated lymphocytes

    by Li-Xin Sun, Wei-Dong Li, Zhi-Bin Lin, Xin-Suo Duan, En-Hong Xing, Miao-Miao Jiang, Ning Yang, Hai-Hua Qi, Yu Sun, Min Li, et al.

    Some cytokines, such as interleukin-2 (IL-2), interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), produced by lymphocytes might play an important role in anti-tumor immunity and their production is possibly suppressed by cancer. Amelioration of the suppression of cytokine production might contribute to cancer control. Ganoderma lucidum polysaccharides (Gl-PS), a versatile group of a component of G. lucidum and one with various bioactivities, might have this potential. In this study, analyses including reverse transcription and the polymerase chain reaction (RT-PCR), immunocytochemistry and Western blot were used to test the effects of Gl-PS on the production of IL-2, IFN-γ and TNF-α in mononuclear lymphocytes by incubating Gl-PS with mouse splenic mononuclear lymphocytes in the presence of B16F10 cell culture supernatant following activation by phytohemagglutinin. The RT-PCR, immunocytochemistry and Western blot assays showed that the production of IL-2, IFN-γ and TNF-α in mononuclear lymphocytes was suppressed by B16F10 cell culture supernatant at both the mRNA and protein levels, whereas the suppression was fully or partially ameliorated by Gl-PS. The amelioration by Gl-PS against the suppression of the production of IL-2, IFN-γ and TNF-α in mononuclear lymphocytes by B16F10 cell culture supernatant might contribute to cancer control.


  • Open Access

    Protection Against Lung Cancer Patient Plasma-Induced Lymphocyte Suppression byGanoderma LucidumPolysaccharides

    by Li-Xin Sun, Wei-Dong Li, Zhi-Bin Lin, Xin-Suo Duan, Xue-Fei Li, Ning Yang, Tian-Fei Lan, Min Li, Yu Sun, Min Yu, et al.

    Background/Aims: This study was conducted to determine the potential of Ganoderma lucidum polysaccharides (Gl-PS) in protection against lung cancer patient plasma-induced suppression of lymphocytes. Lung cancer is a major cause of disease and loss of life in the United States and worldwide. Cancer cells release immunosuppressive mediators, such as PGE2, TGF-β, IL-10, and VEGF, to inhibit the immune response to escape from immune surveillance. Gl-PS has been shown to counteract this immune inhibition in an animal cell culture model, and thus to facilitate tumor control. The present study explored whether or not such an effect could also be demonstrated in human lung cancer patients. Methods: Immunofluorescence, flow cytometry, MTT, immunocytochemistry, and western blot analysis were used to assess lymphocyte activation with PHA. Results: The plasma of lung cancer patients suppressed proliferation, CD69 expression, and perforin and granzyme B production in lymphocytes upon activation by PHA, effects that were partially of fully reversed by Gl-PS. Conclusion: Lung cancer patient plasma-induced suppression of lymphocyte activation by phytohemagglutinin may be antagonized fully or partially by Gl-PS, an observation suggesting the potential of Gl-PS in cancer therapy.